ML-9 HCl | CAS#105637-50-1 | MLC Kinase Inhibitorr

MedKoo Cat#: 525710 | Name: ML-9 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML-9 HCl a is myosin light chain kinase (MLCK) inhibitor. ML-9 enhances the anticancer activity of docetaxel, suggesting its potential application as an adjuvant to existing anticancer chemotherapy. The complex effect of ML-9 on autophagy and indentified ML-9 as an attractive tool for targeting autophagy in cancer therapy through dual inhibition of both the Akt pathway and the autophagy.

Chemical Structure

ML-9 HCl

CAS#105637-50-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 525710

Name: ML-9 HCl

CAS#: 105637-50-1 (HCl)

Chemical Formula: C15H18Cl2N2O2S

Exact Mass: 360.0466

Molecular Weight: 361.29

Elemental Analysis: C, 49.87; H, 5.02; Cl, 19.63; N, 7.75; O, 8.86; S, 8.88

Price and Availability

Size	Price	Availability
100mg	USD 550.00	2 Weeks
200mg	USD 950.00	2 Weeks
500mg	USD 1,850.00	2 Weeks
1g	USD 2,650.00	2 Weeks
2g	USD 3,850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

105637-50-1 (HCl) 110448-31-2 (free base)

Synonym

ML9 HCl; ML-9 HCl; ML 9 HCl, ML-9 hydrochloride

IUPAC/Chemical Name

1-((5-chloronaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride

InChi Key

ZNRYCIVTNLZOGI-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H17ClN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18;/h1-2,4-7,17H,3,8-11H2;1H

SMILES Code

O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 361.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kondratskyi A, Yassine M, Slomianny C, Kondratska K, Gordienko D, Dewailly E, Lehen'kyi V, Skryma R, Prevarskaya N. Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis. 2014 Apr 24;5:e1193. doi: 10.1038/cddis.2014.156. PubMed PMID: 24763050; PubMed Central PMCID: PMC4001310. 2: Ito S, Kume H, Honjo H, Kodama I, Katoh H, Hayashi H, Shimokata K. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis. Eur J Pharmacol. 2004 Feb 23;486(3):325-33. PubMed PMID: 14985055. 3: Honjo M, Inatani M, Kido N, Sawamura T, Yue BY, Honda Y, Tanihara H. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res. 2002 Aug;75(2):135-42. PubMed PMID: 12137759. 4: Kokubu K, Tani E, Nakano M, Minami N, Shindo H. Effects of ML-9 on experimental delayed cerebral vasospasm. J Neurosurg. 1989 Dec;71(6):916-22. PubMed PMID: 2585084. 5: Shi J, Takahashi S, Jin XH, Li YQ, Ito Y, Mori Y, Inoue R. Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells. Br J Pharmacol. 2007 Sep;152(1):122-31. Epub 2007 Jul 2. PubMed PMID: 17603544; PubMed Central PMCID: PMC1978268. 6: Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem. 2000 Nov;128(5):719-22. PubMed PMID: 11056381. 7: Coling DE, Bartolami S, Rhee D, Neelands T. Inhibition of calcium-dependent motility of cochlear outer hair cells by the protein kinase inhibitor, ML-9. Hear Res. 1998 Jan;115(1-2):175-83. PubMed PMID: 9472746. 8: Yamamoto-Yamaguchi Y, Makishima M, Kanatani Y, Kasukabe T, Honma Y. Reversible differentiation of human monoblastic leukemia U937 cells by ML-9, an inhibitor of myosin light chain kinase. Exp Hematol. 1996 May;24(6):682-9. PubMed PMID: 8635523. 9: Barros LF, Marchant RB, Baldwin SA. Dissection of stress-activated glucose transport from insulin-induced glucose transport in mammalian cells using wortmannin and ML-9. Biochem J. 1995 Aug 1;309 ( Pt 3):731-6. PubMed PMID: 7639686; PubMed Central PMCID: PMC1135693. 10: Inoue G, Kuzuya H, Hayashi T, Okamoto M, Yoshimasa Y, Kosaki A, Kono S, Okamoto M, Maeda I, Kubota M, et al. Effects of ML-9 on insulin stimulation of glucose transport in 3T3-L1 adipocytes. J Biol Chem. 1993 Mar 5;268(7):5272-8. PubMed PMID: 7680348. 11: Isemura M, Mita T, Satoh K, Narumi K, Motomiya M. Myosin light chain kinase inhibitors ML-7 and ML-9 inhibit mouse lung carcinoma cell attachment to the fibronectin substratum. Cell Biol Int Rep. 1991 Oct;15(10):965-72. PubMed PMID: 1773444. 12: Nakanishi A, Yoshizumi M, Hamano S, Morita K, Oka M. Myosin light-chain kinase inhibitor, 1-(5-chlornaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-9), inhibits catecholamine secretion from adrenal chromaffin cells by inhibiting Ca2+ uptake into the cells. Biochem Pharmacol. 1989 Aug 15;38(16):2615-9. PubMed PMID: 2764985. 13: Ito M, Tanabe F, Sato A, Ishida E, Takami Y, Shigeta S. Inhibition of natural killer cell-mediated cytotoxicity by ML-9, a selective inhibitor of myosin light chain kinase. Int J Immunopharmacol. 1989;11(2):185-90. PubMed PMID: 2703279. 14: Ishikawa T, Chijiwa T, Hagiwara M, Mamiya S, Saitoh M, Hidaka H. ML-9 inhibits the vascular contraction via the inhibition of myosin light chain phosphorylation. Mol Pharmacol. 1988 Jun;33(6):598-603. PubMed PMID: 3380076.